利福霉素类药物治疗结核病的临床应用研究进展

结核病是由结核分枝杆菌复合群引起的传染性疾病,是全球主要的流行病种之一。利福平是当前最主要的一线抗结核药物,因其长期应用和不规范治疗,利福平耐药逐渐增加,利福喷丁、利福布汀等利福霉素类衍生物在抗结核治疗方面起到了重要作用。基于利福霉素类药物的药理及药动学特性,对该类药物在结核病治疗中进行最优用药选择分析,并对该类药物与其他抗结核药物联用进行综述,旨在为利福霉素类抗结核药物的临床用药提供文献依据。

Research progress on clinical application of rifamycin in treatment of tuberculosis

Tuberculosis is an infectious disease caused by the mycobacterium tuberculosis complex, and is one of the major epidemic diseases in the world. Rifampicin is currently the most important first-line anti-TB drug. Due to its long-term application and non-standard treatment, it has became one of the major epidemics in the world. The cases of multidrug-or rifampicin-resistant tuberculosis increase gradually, and rifampicin derivatives (rifapentine and rifabutin) play an important role in antituberculosis treatment. Based on the pharmacological and pharmacokinetic characteristics of rifamycin, the optimal selection of rifamycin in the treatment of tuberculosis was analyzed, and the combination of rifamycin with other anti-tuberculosis drugs was reviewed. the purpose of this paper is to provide literature basis for the clinical use of rifamycin anti-tuberculosis drugs.